HOXB13 and prostate carcinoma: Although MEIS1 is down-regulated in rituximab-resistant DLCBL cell lines, a recent study reported that the MYC proto-oncogene, bHLH transcription factor (MYC)-dependent down-regulation of MEIS1 is linked to the tumor development and progression via elevated homeobox B13 (HOXB13) expression and androgen receptor (AR) activity in prostate cancers [97], suggesting that the resistance to rituximab may be linked to the down-regulation of MEIS1, which, in turn, could regulate the expression of downstream lncRNAs.